Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group
Francesco Ursini,Piero Ruscitti,Olga Addimanda,Rosario Foti,Vincenzo Raimondo,Giuseppe Murdaca,Virginia Caira,Erika Pigatto,Giovanna Cuomo,Alberto Lo Gullo,Ilaria Cavazzana,Corrado Campochiaro,Caterina Naclerio,Rossella De Angelis,Jacopo Ciaffi,Luana Mancarella,Veronica Brusi,Elena Marchetti,Francesca Motta,Marcella Visentini,Sebastiano Lorusso,Maria De Santis,Giacomo De Luca,Laura Massaro,Domenico Olivo,Roberta Pellegrini,Francesca Francioso,Jessica Luppino,Ilenia Di Cola,Roberta Foti,Giuseppe Varcasia,Francesco Caso,Massimo Reta,Lorenzo Dagna,Carlo Selmi,Annamaria Iagnocco,Roberto Giacomelli,Florenzo Iannone,Clodoveo Ferri
DOI: https://doi.org/10.1136/rmdopen-2023-003022
RMD Open
Abstract:Objectives: To better define the spectrum of new-onset post-COVID-19 and post-COVID-19 vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study. Methods: Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations within 4 weeks from the administration of one of the COVID-19 vaccines ws recruited. Results: The final analysis cohort comprised 267 patients, of which 122 (45.2%) in the post-COVID-19 and 145 (54.8%) in the postvaccine cohort. Distribution of IRD categories differed between the two cohorts: the post-COVID-19 cohort had a higher percentage of patients classified as having inflammatory joint diseases (IJD, 52.5% vs 37.2%, p=0.013) while the post-vaccine cohort had a higher prevalence of patients classified as polymyalgia rheumatica (PMR, 33.1% vs 21.3%, p=0.032). No differences were detected in the percentage of patients diagnosed with connective tissue diseases (CTD 19.7% vs 20.7%, p=0.837) or vasculitis (6.6% vs 9.0%, p=0.467). Despite the short follow-up period, IJD and PMR patients' response to first-line therapy was favourable, with both groups achieving a drop in baseline disease activity scores of ~30% and ~70% respectively. Conclusion: Our article reports the largest cohort published to date of new-onset IRD following SARS-CoV-2 infection or COVID-19 vaccines. Although causality cannot be ascertained, the spectrum of possible clinical manifestations is broad and includes IJD, PMR, CTD and vasculitis.